Ophthalmic solution of difluprednate

Patent metadata

Field	Value
Publication number	US-11103451-B2
Application number	US-201615768316-A
Country	US
Kind code	B2
Filing date	Oct 15, 2016
Priority date	Oct 16, 2015
Publication date	Aug 31, 2021
Grant date	Aug 31, 2021

Abstract

The present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day. The present invention also provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives.

First claim

The invention claimed is:

1. A method of treating an inflammatory disorder of the eye, said method comprising administering twice-a-day, a clear aqueous solution comprising, in an aqueous vehicle:
a. about 0.02% w/v to about 0.04% w/v difluprednate, wherein the difluprednate is not in microparticulate form;
b. about 0.5% w/v to about 3.0% w/v of polyvinyl alcohol or derivative thereof; and
c. a solubilizer comprising (i) about 0.01% w/v to about 0.05% w/v quaternary ammonium compound and (ii) about 1.5% w/v to about 6.0% w/v polyethoxylated castor oil;
into the eye of a person in need thereof.

2. The method as claimed in claim 1 , wherein the inflammatory disorder of the eye is selected from the group consisting of pain and inflammation associated with ocular surgery and uveitis.

3. The method as claimed in claim 1 , wherein the inflammatory disorder of the eye is acute anterior uveitis or chronic uveitis.

4. The method as claimed in claim 1 , wherein the difluprednate is present at a concentration of 0.04% weight by volume.

5. The method as claimed in claim 1 , wherein the difluprednate is present at a concentration of 0.03% weight by volume.

6. The method of claim 1 , wherein the difluprednate is about 0.03% w/v to about 0.04% w/v.

7. The method of claim 1 , wherein the polyvinyl alcohol or derivative thereof is about 1.4% w/v.

8. The method of claim 1 , wherein the polyvinyl alcohol or derivative thereof is about 3.0% w/v.

9. The method of claim 1 , wherein the quaternary ammonium compound is benzalkonium chloride.

10. The method of claim 1 , wherein the quaternary ammonium compound is about is about 0.025% w/v.

11. The method of claim 1 , wherein the polyethoxylated castor oil is polyoxyl 35 castor oil.

12. The method of claim 1 , wherein the polyethoxylated castor oil is about 3.0% w/v to about 5.0% w/v.

13. The method of claim 1 , wherein the polyethoxylated castor oil is about 5.0% w/v.

14. The method of claim 1 , wherein the clear aqueous solution further comprises a preservative selected from biguanide, boric acid, n-lauryl sarcosine, or a combination thereof.

15. The method of claim 1 , wherein solution percent transmission of the clear aqueous solution is greater than 90%.

16. A method of treating an inflammatory disorder of the eye, said method comprising administering a clear aqueous solution comprising, in an aqueous vehicle:
a. about 0.03% w/v to about 0.04% w/v difluprednate,
b. about 0.5% w/v to about 3.0% w/v polyvinyl alcohol or derivative thereof,
c. about 0.01% w/v to about 0.05% w/v benzalkonium chloride; and
d. about 1.5% w/v to about 6.0% w/v polyoxyl 35 castor oil,
into the eye of a person in need thereof.

17. The method of claim 16 , wherein the method comprises administering the clear aqueous solution into the eye of a person in need thereof twice a day.

Assignees

• Sun Pharma Advanced Res Co Ltd

Inventors

• Khopade Ajay Jaysingh
• Halder Arindam
• Shah Ankit Shaileshkumar

Classifications

• A61K31/573 Primary

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/08 Primary

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/44

  Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) · CPC title